Tilray, Inc is a drug manufacturers-specialty & generic business based in the US. Tilray shares (TLRY.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.02 – a decrease of 8.53% over the previous week. Tilray employs 1,646 staff and has a trailing 12-month revenue of around $183.1 million.
|Latest market close||$18.02|
|52-week range||$2.43 - $22.61|
|50-day moving average||$11.0545|
|200-day moving average||$7.7568|
|Wall St. target price||$10.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.23|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-15)||-8.53%|
|1 month (2020-12-24)||109.78%|
|3 months (2020-10-23)||167.76%|
|6 months (2020-07-24)||153.09%|
|1 year (2020-01-24)||-8.76%|
|2 years (2019-01-24)||-75.64%|
|Revenue TTM||$183.1 million|
|Gross profit TTM||$-21,455,000|
|Return on assets TTM||-15.13%|
|Return on equity TTM||-161.76%|
|Market capitalisation||$2.9 billion|
TTM: trailing 12 months
There are currently 27.7 million Tilray shares held short by investors – that's known as Tilray's "short interest". This figure is 3.3% up from 26.8 million last month.
There are a few different ways that this level of interest in shorting Tilray shares can be evaluated.
Tilray's "short interest ratio" (SIR) is the quantity of Tilray shares currently shorted divided by the average quantity of Tilray shares traded daily (recently around 21.3 million). Tilray's SIR currently stands at 1.3. In other words for every 100,000 Tilray shares traded daily on the market, roughly 1300 shares are currently held short.
However Tilray's short interest can also be evaluated against the total number of Tilray shares, or, against the total number of tradable Tilray shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tilray's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Tilray shares in existence, roughly 180 shares are currently held short) or 0.1843% of the tradable shares (for every 100,000 tradable Tilray shares, roughly 184 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tilray.
Find out more about how you can short Tilray stock.
We're not expecting Tilray to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Tilray's shares have ranged in value from as little as $2.43 up to $22.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 3.108. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, Israel, Ireland, New Zealand, South Africa, Switzerland, the United States, and the United Kingdom. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.